ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis
USA - NASDAQ:ATRA - US0465132068 - Common Stock
14.35 USD
+0.61 (+4.44%)
13.65 USD
-0.7 (-4.88%)
Taking everything into account, ATRA scores 4 out of 10 in our fundamental rating. ATRA was compared to 533 industry peers in the Biotechnology industry. There are concerns on the financial health of ATRA while its profitability can be described as average. ATRA has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ATRA was profitable.
In the past year ATRA has reported a negative cash flow from operations.
ATRA had negative earnings in each of the past 5 years.
ATRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 77.57%, ATRA belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
ATRA has a better Return On Invested Capital (271.93%) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.57% | ||
| ROE | N/A | ||
| ROIC | 271.93% |
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATRA has a better Profit Margin (15.40%) than 93.06% of its industry peers.
The Operating Margin of ATRA (27.44%) is better than 95.87% of its industry peers.
ATRA has a Gross Margin of 81.63%. This is amongst the best in the industry. ATRA outperforms 85.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.44% | ||
| PM (TTM) | 15.4% | ||
| GM | 81.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATRA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ATRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ATRA has less shares outstanding
Compared to 1 year ago, ATRA has a worse debt to assets ratio.
2.2 Solvency
ATRA has an Altman-Z score of -83.20. This is a bad value and indicates that ATRA is not financially healthy and even has some risk of bankruptcy.
ATRA has a worse Altman-Z score (-83.20) than 95.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -83.2 |
ROIC/WACC36.26
WACC7.5%
2.3 Liquidity
ATRA has a Current Ratio of 1.02. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
ATRA has a worse Current ratio (1.02) than 87.62% of its industry peers.
ATRA has a Quick Ratio of 1.02. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.02, ATRA is not doing good in the industry: 86.68% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 108.46%, which is quite impressive.
ATRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 51.27%.
ATRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 85.07% yearly.
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
3.2 Future
The Earnings Per Share is expected to grow by 18.75% on average over the next years. This is quite good.
Based on estimates for the next years, ATRA will show a small growth in Revenue. The Revenue will grow by 5.91% on average per year.
EPS Next Y112.23%
EPS Next 2Y39.56%
EPS Next 3Y16.81%
EPS Next 5Y18.75%
Revenue Next Year3.31%
Revenue Next 2Y-32.22%
Revenue Next 3Y-65.7%
Revenue Next 5Y5.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ATRA is valuated cheaply with a Price/Earnings ratio of 6.58.
Based on the Price/Earnings ratio, ATRA is valued cheaply inside the industry as 98.31% of the companies are valued more expensively.
ATRA is valuated cheaply when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
ATRA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.58 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ATRA is valued cheaper than 99.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.6 |
4.3 Compensation for Growth
ATRA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ATRA's earnings are expected to grow with 16.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y39.56%
EPS Next 3Y16.81%
5. Dividend
5.1 Amount
ATRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.35
+0.61 (+4.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.73%
Inst Owner Change4.39%
Ins Owners1.77%
Ins Owner Change1.19%
Market Cap100.74M
Revenue(TTM)151.93M
Net Income(TTM)23.40M
Analysts80
Price Target16.83 (17.28%)
Short Float %3.05%
Short Ratio2.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.01%
Min EPS beat(2)63.52%
Max EPS beat(2)140.49%
EPS beat(4)4
Avg EPS beat(4)136.18%
Min EPS beat(4)63.52%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)49.96%
EPS beat(12)7
Avg EPS beat(12)23.63%
EPS beat(16)9
Avg EPS beat(16)20.25%
Revenue beat(2)2
Avg Revenue beat(2)138.29%
Min Revenue beat(2)134.43%
Max Revenue beat(2)142.15%
Revenue beat(4)4
Avg Revenue beat(4)485.59%
Min Revenue beat(4)67.7%
Max Revenue beat(4)1598.08%
Revenue beat(8)6
Avg Revenue beat(8)233.67%
Revenue beat(12)6
Avg Revenue beat(12)128.56%
Revenue beat(16)8
Avg Revenue beat(16)133.26%
PT rev (1m)0%
PT rev (3m)-2.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-41.84%
EPS NY rev (1m)0%
EPS NY rev (3m)199.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)77.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.58 | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 2.6 |
EPS(TTM)2.18
EY15.19%
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-9.94
FCFYN/A
OCF(TTM)-9.93
OCFYN/A
SpS21.64
BVpS-5.22
TBVpS-5.22
PEG (NY)0.06
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 77.57% | ||
| ROE | N/A | ||
| ROCE | 344.22% | ||
| ROIC | 271.93% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 27.44% | ||
| PM (TTM) | 15.4% | ||
| GM | 81.63% | ||
| FCFM | N/A |
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover5.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.71 | ||
| Cap/Depr | 2.84% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | 116.11 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -83.2 |
F-Score4
WACC7.5%
ROIC/WACC36.26
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
EPS Next Y112.23%
EPS Next 2Y39.56%
EPS Next 3Y16.81%
EPS Next 5Y18.75%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
Revenue Next Year3.31%
Revenue Next 2Y-32.22%
Revenue Next 3Y-65.7%
Revenue Next 5Y5.91%
EBIT growth 1Y134.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year129.89%
EBIT Next 3Y14.87%
EBIT Next 5Y-3.99%
FCF growth 1Y65.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.05%
OCF growth 3YN/A
OCF growth 5YN/A
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
Can you provide the ChartMill fundamental rating for ATARA BIOTHERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to ATRA.
What is the valuation status for ATRA stock?
ChartMill assigns a valuation rating of 5 / 10 to ATARA BIOTHERAPEUTICS INC (ATRA). This can be considered as Fairly Valued.
How profitable is ATARA BIOTHERAPEUTICS INC (ATRA) stock?
ATARA BIOTHERAPEUTICS INC (ATRA) has a profitability rating of 4 / 10.
What are the PE and PB ratios of ATARA BIOTHERAPEUTICS INC (ATRA) stock?
The Price/Earnings (PE) ratio for ATARA BIOTHERAPEUTICS INC (ATRA) is 6.58 and the Price/Book (PB) ratio is -2.75.
What is the earnings growth outlook for ATARA BIOTHERAPEUTICS INC?
The Earnings per Share (EPS) of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 112.23% in the next year.